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The three day conference on Antimicrobial Resistance:
A Cause for Global Concern was organized from 6-8th
February, 2012 by the Department of Microbiology and
Fermentation Technology, Sam Higginbottom Institute
of Agriculture, Technology and Sciences (SHIATS)
[Deemed-to-be-University], Allahabad, India. The con-
ference received an overwhelming response from three
hundred participants including scientists, medical pro-
fessionals, academicians, industrialists and students from
all quarters of the country. Participation from the Clini-
cal and Laboratory Standards Institute, USA also made
a remarkable contribution to the event.
Elaborating on the focal area of the event, Organizing
Secretary and Convener Prof. (Dr.) Rubina Lawrence,
spoke on the significance of miracle drugs in the treatment
of infectious diseases. She emphasised the chemical reper-
cussions of the chemical warfare waged against microbes
through therapeutic and non-therapeutic uses of antimi-
crobial agents. She highlighted the global problem of anti-
microbial resistance (AR) which is particularly pressing in
developing countries where the infectious disease burden is
high, there are cost constraints on testing to identify resis-
tant infections and using newer and more expensive agents
to treat them. In her address she illustrated the recent
survey which emphasized that “Antibiotic resistance is a
burgeoning problem in India”. Due to availability of over-
the-counter antibiotics and their improper and rampant
use, antibiotic resistance in the Indian population has
skyrocketed. The future is however not entirely gloomy.
The global strategy of WHO for the containment of anti-
microbial resistance was underlined in her talk. However
significant gaps in knowledge, research and development
(R & D), funding and policy remain, particularly in
developing countries. Prof. Lawrence, stated that the
Second National Conference on Antimicrobial Resistance:
A Cause for Global Concern is a follow-up to the first
national conference organized in the year 2009 that was
organized to further re-assess, consolidate the latest picture
of the issue and the challenges faced thereof through the
years. Concluding her talk she said that the conference is
ventured to address this peril and to formulate strategies to
combat it.
The popular consensus was that the conference suc-
ceeded effectively in attaining the various interlinked
fields in contributing to analyse the problem of antimi-
crobial resistance. Presentations made under the five
major subthemes are described below.
Clinical challenges in addressing resistance to
antimicrobial drugs in the 21st century
Dr. K. Venkatesan, Scientist F/Deputy Director, National
JALMA Institute of Leprosy and Other Mycobacterial dis-
eases, Agra focused his talk on tuberculosis by stating it as
one of the leading causes of mortality in India, killing two
people every three minutes i.e., nearly 1,000 per day as
reported by the Directorate of Health Services, India in
2009 while an estimated 2 billion people are infected with
the pathogen worldwide. He quoted a study conducted on
a cohort of patients from urban population in Mumbai
reporting a high incidence of MDR-MTB (51%) [1]. He
further expressed that a rise in MDR-TB cases, accounting
to about 5% of 9 million of all types of TB in several coun-
tries, is a cause of great concern that threatens the success
of DOTS (directly observed treatment, short course); the
WHO recommended treatment approach for detection
and cure of tuberculosis [2].
As the burden of MDR/XDR-TB is growing, strategies
to combat its emergence include having clear policies,
radical change in policies, optimal management of exist-
ing cases, steps to intensify R & D for rapid diagnostics
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and discovery of new drugs. He further stressed on the
core policy packages of World Health Day 2011 in the
commitment of a comprehensive, financed national plan
with accountability and civil society engagement. This
will help in strengthening surveillance and laboratory
capacity, ensuring regular supply of good quality medi-
cines, regulating and promoting rational use of medicines
including animal medicines, ensuring proper patient and
animal care, enhancing infection prevention and control
in human and animals, fostering innovations, R & D of
new technologies and medicinal products.
Dr. Rama Chaudhary, Professor, Department of Micro-
biology, All India Institute of Medical Sciences, New Delhi
discussed epidemiology and risk factors for Clostridium
difficile in cases of antibiotic associated diarrhoea (AAD)
being the primary causative agent. She highlighted the sig-
nificance of molecular characterization of C. difficile and
stressed the need to screen for the organism in patients
with antibiotic associated diarrhoea. Dr. Chaudhary con-
cluded that analysis of C. difficile isolates from different
geographical regions within the country should be done
using a molecular approach to rule out the presence of the
hyper virulent strain in the Indian setting.
The clinical and microbiological perspectives of ESBL
infections were illustrated in the presentation of Prof.
(Dr.) K. N. Prasad, Department of Microbiology, Sanjay
Gandhi Postgraduate Institute, Lucknow. He stated that
in India, bacteria are now producing multiple types of
beta-lactamases. With limited treatment options avail-
able, there is a need to optimize the use of antibiotics
against rapid proliferation of the bugs, since failure to
do so will eventually lead to a pre-antibiotic era. The
right drug, dose and duration were the 3 Ds explained
by him for optimization. The antibiotic therapy was
classified on the basis of a time dependent and concen-
tration dependent treatment approach. He further stated
that with the increase in minimum inhibitory concentra-
tion (MIC) in recent years, blood levels of antibiotics are
not sufficient to remain above MIC for >40-60% time of
dosing interval. Combinations of beta-lactamase inhibi-
tors (BLI) along with cefepime and cefpirome deserve
evaluation as alternatives to carbapenems in severe
ESBL infections.
Prof. Prasad said that ESBL testing should be routinely
done for epidemiological studies. Sensitivity testing for
more than one third-generation cephalosporin should be
done on a routine basis. He suggested that clinical
microbiologists should encourage de-escalation and pro-
vide actual MICs for MDR pathogens. Discs available
for all carbapenems should be tested since S/R of one
carbapenem cannot extrapolate to another. Further,
training should be given to clinicians on MIC break-
points and optimization of dosage. Some of the steps to
prevent infections elucidated by Prof. Prasad were
barrier precautions during catheter insertion and care,
surveillance for catheter-related infections and timely
drain out of catheter line, to target the pathogen not the
contaminant/colonizer, to practice empiric therapy to
likely pathogens and target definite therapy to known
pathogens. Some of the other measures highlighted by
him were to consult infectious disease specialists/clinical
microbiologists for patients with serious infections, stop
unnecessary use of antibiotics, consider de-escalation to
prevent co-lateral damage and to break the chain of
transmission through hand wash or hand rub. He con-
cluded his talk with an emphasis on awareness programs
for patients to avoid use of expensive antibiotics and to
promote hygienic and hand sanitation practices.
Prof. (Dr.) Pallab Ray from the Department of Medi-
cal Microbiology, Postgraduate Institute of Medical
Research and Education, Chandigarh spoke on the phar-
macokinetic and pharmacodynamic approaches to com-
bating drug resistance.
To optimize treatment in critically ill patients with infec-
tions, Dr. Ray said that in vitro susceptibility of the patho-
gen holds equal importance to the right choice of
antibiotic to solve the antimicrobial therapy puzzle. Taking
into account the pathophysiological and immunological
status of the patient, the selection of the right antimicro-
bial, timely administration, its route, dosage, schedule and
duration is mandatory. He suggested that in most cases
7-10 days therapy is adequate and a shorter course with
better clinical outcome can result in fewer subsequent
superinfections with MDR pathogens. He further empha-
sized on the importance of procalcitonin as a biomarker to
monitor the efficacy of treatment. He concluded his talk
by stating that appropriate antimicrobials alone are not
adequate for therapy; appropriate regimen should also be
followed to reduce the emergence of drug resistance.
Dr. Sanyog Jain, Department of Pharmaceutics,
National Institute of Pharmaceutical Education and
Research, SAS Nagar, Punjab, drew attention to the
nanodrug delivery system as a rational approach to
combat multi-drug resistance in microorganisms. The
current scenario of antimicrobial therapy demands a
high degree of counter mechanism to prevent wide
spread multiple drug resistance. One among the race
can be the formulated strategy in which nanodrug deliv-
ery system can be efficiently exploited to combat multi-
ple drug resistance, as suggested by Dr. Jain. He further
stated that the novel formulations are capable of bypass-
ing the most common route of multiple drug resistance
and altered pharmacokinetics thus can achieve higher
therapeutic efficacy at lower doses. Various nano-formu-
lations such as liposomes or nanoparticles have been
evaluated to establish the superior therapeutic outcome
as compared to conventional therapy. Furthermore, the
targeting potential of these new drug delivery systems
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can be selectively implemented to combat multiple drug
resistance.
The lecture of Dr. Sukla Biswas, Emeritus Scientist,
National Malarial Research Institute, New Delhi focused
on the molecular mechanisms of antimalarial drug resis-
tance. Higher malaria morbidity and mortality, increased
cost of malaria case management, increased burden on
the health care facilities, predisposition of malaria epi-
demics and increased relative prevalence of Plasmodium
falciparum were outlined to be responsible for drug
resistant malaria in India. The important aspects for the
successful implementation of antimalarial drugs illu-
strated by her were: good tolerability, affordability, avail-
ability in endemic areas and short course regimens. As
per the reports of Dr. Biswas, drug resistance is seen
predominantly in P. falciparum as compared to P. vivax.
The SP (sulphadoxine/pyrimethamine) failure rate in
P. falciparum has increased from 7.7% during 1994-96
to 25.9% during 1997-2007. Her studies depicted that
parasites isolated from the Nalbari and Dalu districts of
Assam were highly polymorphic, though Nalbari isolates
revealed relatively high diversity. A high degree of
multi-clone infections could be an adaptive feature for
parasitic survival in high endemic regions. High preva-
lence of drug resistance revealed mutations in dhfr, dhps
and Pfcrt genes. For treatment of P. falciparum malaria,
the ACT (artesimate + sulfadoxine – pyrimethamine)
resulted in rapid parasite clearance well within a day or
two with a cumulative cure rate of 95.3%. This drug
regimen was well tolerated and concluded to be safe
and effective. The prevalence of quintuple mutation
(DHFR triple mutation and DHPS double mutation) can
be used as a tool to screen clinical isolates by PCR
based assay for monitoring SP clearance. Dr. Biswas
explained that the emergence and spread of resistance is
influenced by interactions between the malarial para-
sites, vectors, antimalarial drugs and humans. She
further suggested that continued surveillance to analyse
mutations of target molecules may also offer a useful
tool in epidemiological surveys for drug resistance. She
said that formulation of malarial treatment policies,
measures to curb malaria morbidity and mortality and
planning of cost-effective malaria control are some of
the key areas to be focused on.
Prof. (Dr.) Gopal Nath, Head, Department of Micro-
biology, Banaras Hindu University, Varanasi said that
the increasing trend of antibiotic resistance among
superbugs has led to the search for alternatives like anti-
microbial peptides, bacteriocins, probiotics and bacterio-
phages. Elaborating his talk on bacteriophage therapy,
Dr. Nath divided the history of phage therapy into four
periods: early enthusiasm, critical scepticism, abandon-
ment and recent interest and reappraisal.
Although phage therapy trials in United States and most
of Western Europe ceased after World War-II, probably
due to widespread success and the availability of antibio-
tics, it is still being actively pursued in Soviet Union and
some other Eastern European countries. Phage therapy
has been tried extensively which is reflected by the fact
that nearly 800 papers have been published during 1917-
1957. Nevertheless, the reports were variable, which was
explained to be due to the paucity of understanding of het-
erogeneity and ecology of both the phages and bacteria
involved, failure to select phage of high virulence against
the target bacteria before using them on patients and use
of single phage in infections which involved mixtures of
different bacteria.
Dr. Nath illustrated with the classical example of super
bug Pseudomonas aeruginosa, which is notorious as it
gains resistance from its environment. To achieve an
effective control of infections caused by Pseudomonas
sp., Dr. Nath isolated bacteriophages from different
sources and checked their activity on different clinical
isolates of Pseudomonas aeruginosa. On the basis of the
dendogram constructed, phages with similar activity were
identified and among them the most active viruses were
selected to make a cocktail for the therapy of the mouse
burn Pseudomonas aeruginosa septicaemia model.
Prof. (Dr.) Varsha Gupta, Department of Microbiol-
ogy, Government Medical College Hospital, Chandigarh
spoke on the epidemiological and therapeutic challenges
of ESBLs in India. She explained that the pattern of ESBL
infections differ in community and hospital with respect
to the organism, type of ESBL, type of infection, molecu-
lar epidemiology and geographical breadth/epidemiology.
The global figures projected by her showed that almost
every part of the globe is affected by ESBL positivity. In
the Indian scenario, ESBL was first reported in Nagpur
during 1997, followed by several reports from Delhi and
until 2009 Sanjay Gandhi Postgraduate Institute of Medi-
cal Sciences, Lucknow reported rates of up to 70% in
Escherichia coli. Genotype studies of the ESBLs showed
higher incidence of CTX-M followed by TEM with least
incidence of SHV type of ESBL. However, reports on the
global incidence of ESBL genotypes represent SHV,
TEM, CTX-M and others (VEB, VER, BEL-1, BES-1,
SFO-1, TLA and IBC). Dr. Gupta quoted a few genotypic
studies that have been conducted in India (hospitals and
community) during her presentation. In Southern India,
SHV-12 was reported in Klebsiella pneumoniae. SHV-5
and TEM-104 in Salmonella seftenberg and K. pneumo-
niae isolates in Delhi and CTX-M-15 in Escherichia coli
and K. pneumoniae in New Delhi and Coimbatore,
respectively have been reported.
With the present drug resistance pattern, Prof. Gupta
suggested that carbapenems are the first line agents which
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could be effectively used in the treatment. She said that no
randomized control trials (RCTs) are available from India
but data from case series and retrospective studies show
positive results. These carbapenems also have a high
inoculum effect and the members suggested were ertape-
nem, imipenem, meropenem and doripenem. Further
beta-lactam and beta-lactam inhibitor combinations sug-
gested by her were clavulanic acid, sulbactum and tazobac-
tum. Tazobactum was found to be the most potent
followed by clavulanic acid as they were active against
TEM, SHV and CTX-M. The other drugs suggested by
her were piperacillin and tazobactum with favourable
results. Clavulante was shown to be a good inhibitor for
detection of ESBL. She further said that though antibiotic
combinations viz., amoxycillin - clavulanic acid and ticar-
cillin – clavulanic acid, showed borderline activity, they
did not work when ESBL and AmpC together were found
in the organism. Clavalunate was found to be effective
against CTX-M-15 and not against OXA-1 even though
CTX-M-15 and OXA-1 are determined by the same plas-
mid i.e. common occurrence. Tigecycline has been
approved by US FDA for complicated intra-abdominal
infections (IAIs) and skin and soft tissue infections
(SSTIs). Limited clinical data is available from India where
tigecycline is not used for UTI since it is not excreted in
the urinary tract. Moreover, after intravenous infusion,
rapid tissue distribution occurs; hence it is of great con-
cern when used in blood stream infections. In ventilator
associated pneumoniae (VAP), imipenem is better than
tigecycline. Her lecture depicted that despite in vitro sus-
ceptibility of cephalosporins, worst outcome was found
and hence not recommend for ESBL infections. She
emphasized that aminoglycosides, fluoroquinolones and
cotrimoxazole should be used with caution in serious
infections even after documentation of in vitro activity.
Fluoroquinolones are an excellent option for UTI patients
with ESBLs if the organism is susceptible. However, ami-
noglycosides should never be used in monotherapy but
can be useful as adjuncts. There is no CLSI breakpoint for
susceptibility of colistin against Enterobacteriaceae but E-
test has been proposed. She said that some of the newer
drugs like fosfomycin, temocillin and pivmecillinam are
unfortunately not available in India. Fosfomycin is
approved by US FDA for treatment of uncomplicated
UTI. In vitro studies show that fosfomycin is active against
ESBL producing E. coli and Klebsiella sp. Fosfomycin
E-strip has been used by Dr. Gupta against ESBL for
laboratory testing. Temocillin is a derivative of ticarcillin
and is stable to beta-lactamase action, well tolerated, and
licensed in the UK and Belgium. Similarly mecillinam is
also under testing in her laboratory. She stated that other
carbapenems like biapenem and feropenem are soon to be
available in the market.
Dr. Gupta further suggested that control of infections
from the reservoirs like GIT, orpharynx, colonized
wounds, urine and community with ESBLs should be
done. Measures should be taken to adopt proper infection
control practices such as: hand washing, barrier precau-
tions, isolation of colonized or infected patients, surveil-
lance of patients of ICUs, early detection, antibiotic
restriction and antibiotic restriction strategies. She con-
cluded by stating that ESBLs are distributed world-wide
and the major challenge is therapy of severe infections.
The lecture of Dr. Deepa Bisht, Scientist C, Senior
Research Officer, Department of Biochemistry, National
JALMA Institute of Leprosy and Other Mycobacterial
Diseases, Agra was focused on the proteomic approach
for identifying drug targets in mycobacteria. She
explained that using a proteomic approach, identifica-
tion of drug targets, development of vaccines and diag-
nostics for tuberculosis can be achieved. Dr. Bisht
illustrated that as per the estimates of WHO, [2], 9.27
million new cases were reported world-wide with 1.8
million deaths. India accounts for one fifth of the global
incidence with 1.9 million new cases and 0.3 million
deaths. The enormity of the problem has been further
worsened by widespread development of MDR-TB and
XDR-TB. She stated that the prevalence of MDR-TB is
about 3% in new cases and 12-17% in re-treatment
cases in India. Treatment success rates have tripled
from 25-86% and death rates have been cut 7-fold from
29% to 4% in comparison to the pre-RNTCP (Revised
National Tuberculosis Control program) era.
She said that aminoglycosides are major second line anti-
tuberculosis drugs for treatment of resistant tuberculosis.
In order to understand the biology of M. tuberculosis, pro-
teomics could be used as a complementary tool for geno-
mic comparisons. The challenges for proteomics outlined
by her were analysis of low abundance proteins and protein
interaction studies, where native conformations of proteins
must be maintained to obtain meaningful results. She sta-
ted that most of the proteomic approach relies on methods
that are not high-throughput methods. New technologies
will have to emerge before protein analysis on a large scale
becomes a reality.
Antibiotics, agriculture and super bugs
Prof. (Dr.) Brahma Dutta Kaushik, Dean, College of
Biotechnology, Anand Engineering College, Agra
addressed his keynote lecture on the topic “Next genera-
tion super bugs; Microalgae as key unexplored reservoirs
of bioactive metabolites”. Prof. Kaushik in his lecture
described the significance of cyanobacteria by stating
that it produces a number of secondary metabolites,
allelochemicals and enzymes which exhibit bioactivities
such as inhibitory properties against microorganisms
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and toxicity to invertebrates and vertebrates. These
metabolites can be used for development and applica-
tion as algicides, fungicides, herbicides and insecticides.
Such allelopathic compounds have various modes of
action: from inhibition of photosynthesis to oxidative
stresses or cellular paralysis. However, presently the use
of these metabolites in agriculture is limited. He said
that the cyanobacterial metabolites (cyanotoxins) are
allelochemicals which provide a competitive advantage
to the producer, are novel compounds with diverse
bioactivities, act as an antifungal agent (i.e., with bio-
control properties) and biopesticides and also possess
cytotoxic properties (i.e., with anticancer or antitumor
agents).
While concluding his lecture Dr. Kaushik said that
Cyanobacteria are key to any understanding of the
Earth’s early biology and environmental history. He sta-
ted that developing tight linkages with crop plants is
needed for efficient nutritional interactions, thus
improving plant productivity. Gene mining can help to
explore and excavate novel genes and bioactive mole-
cules. Cyanobacteria are natural candidates for seedling
inoculation, especially in reforestation and rehabilitation
of coastal systems, and need to be exploited.
The second key note address was presented by
Dr. Debashish Chattopadhyay, Additional Director
(Microbiology), National Centre for Disease Control,
New Delhi. He spoke on “Antibiotic resistance markers
in genetically modified plants: An evaluation of possible
human risk”. The sunny sides of genetically modified
foods explained by him were: plants with increased
yields, nutrient content, herbicide tolerant plants, insect
resistant plants, animals with a better yield of products
(e.g. milk, meat), plants producing drugs, vaccines and
lower levels of greenhouse gas emission. On the dark
side he emphasized the safety issues like deletion/sup-
pression of useful nutrients, insertion/activation of anti-
nutrients, insertion/activation of allergens and the
potential transfer of the antibiotic resistant marker
(ARM) gene in GM food to the human body through
incorporation into gut flora.
The risk groupings of ARMs as discussed by him were
Group I, Group II and Group III. Group I (e.g. npt II) is of
very little clinical utility and has high prevalence in the
gut. Neomycin phosphotransferase II (npt II) confers resis-
tance to the aminoglycoside group of antibiotics e.g. neo-
mycin (used for gut sterilization) and kanamycin (little
clinical application); both of which have high prevalence of
resistance in the gut and environment. In Group II the sig-
nificance of bla (beta lactamase) and aad-A (aminoglyco-
side-o-nucleotidyl transferase) were discussed. He
explained that bla mainly confers resistance to ampicillin
and penicillin, has moderate clinical application and mod-
erate prevalence in the gut and environment [3]. The bla
gene product b-lactamase hydrolyses penicillin. He further
added that there is a chance of the emergence of ESBL
production by bacteria under selection pressure of contin-
ued use of this category of antibiotics, therefore there is a
requirement for a newer generation of antibiotics e.g., car-
bapenems. On the other hand, aad confers resistance to
streptomycin which is still the drug of choice for tubercu-
losis in the resource-poor developing countries and specti-
nomycin which is the second line treatment for anogenital
and joint infections due to Gonococcus. npt III is included
under Group III. This has higher clinical utility and low
prevalence in the gut and environment. This marker is
used for experiments only and not for production of GM
crops. He mentioned that the overall risk of transfer of
antibiotic resistance through DNA is minimal due to the
negligible quantity and heterogeneity of source DNA,
extremely low rate of its transfer under experimental con-
ditions, loss of integrity during food processing, passage
through the GI tract and so on.
Dr. Gerard Abraham, Principal Scientist, Centre for
Conservation and Utilization of Blue Green Algae, Indian
Agricultural Research Institute, New Delhi presented his
lecture on antimicrobial activity of Azolla microphylla. He
said that seasons play an important role in the secondary
metabolite profile of A. microphylla. In his study, extracts
of Azolla microphylla showed significant antibacterial but
no antifungal activity; suggesting that this organism can be
exploited as a source for antagonistic compounds. How-
ever, the proteomic profile needs to be investigated to
further understand the involvement of other molecules in
antagonistic response.
Dr. Bhoj Raj Singh, Principal Scientist, Joint Directors
Lab, Centre for Animal Disease and Diagnosis, Indian
Veterinary Research Institute, Izatnagar, Bareilly presented
a thought provoking issue i.e., “The positive aspect on the
emergence of antibiotic drug resistance (ADR) in the exis-
tence of life on earth”. In the lecture, Dr. Singh suggested
that bacteria are the major scavengers that play a signifi-
cant role in keeping the earth liveable; their survival is
probably more important than ours, that is why nature
has protected them through the development of ADR.
Dr. Rajesh Kumar Vaid, Senior Scientist (Veterinary
Public Health), Veterinary Type Culture Centre,
National Research Centre on Equines, Hisar spoke on
antimicrobials and their judicious use in livestock. He
said that antimicrobial use in food animals can lead to
selection of antimicrobial resistant zoonotic enteric
pathogens. These are transferred to people via food or
animal contact. Further, resistant bacteria excreted in
the faeces of animals having received antimicrobials
serve as a reservoir in the environment. These are the
issues in antimicrobial resistance in veterinary medicine
as outlined by Dr. Vaid. The factors that may contribute
to the antimicrobial resistance as elaborated by him
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were indiscriminate use of antimicrobials in animal agri-
culture/aquaculture which may contribute to the envir-
onmental reservoir of resistant microbes, trend towards
intensive livestock production, more animals per farm
and susceptible animals in close physical contact. In
addition, increasing international travel and trade can
also add to this problem. However, there are controver-
sies with regard to concerns on the impact of use of
antimicrobials in animals on public health. Dr. Vaid sta-
ted that antimicrobials used in livestock to control Sal-
monella and E. coli are of great concern as antibiotic
resistance developed in these pathogens are subse-
quently transferred to humans through contaminated
food. He concluded his lecture by saying that stringent
adoption and enforcement of OIE (Office International
des Epizooties) guidelines/List of AMs in Veterinary
medicine/CE credits should be done, training and appli-
cation of international/standard laboratory procedures
in antimicrobial susceptibility testing should be adopted,
there should be increased surveillance, monitoring and
reporting of anti-microbial drug resistance-epidemiologi-
cal cut-off values from microbes of veterinary origin. He
also recommended to focus research particularly on
organisms like Salmonella, Escherichia coli, Klebsiella,
Staphylococcus, Streptococcus, Pasteurella spp. etc. He
added that research on discovery and application of bio-
security, hygiene, vaccination, probiotics, prebiotics and
essential oils for growth promotion should be encour-
aged. Research on novel antimicrobials such as RAMPs
(receptor activity-modifying proteins) like defensins
should be conducted.
The presentation of Dr. Ravinder Kumar, Depart-
ment of Biotechnology, KVA DAV College for Women,
Karnal was a depiction on the distribution of multiple
antibiotic resistance genes and pathogenic factors of Sta-
phylococcus aureus isolates that has raised the alarming
situation on the safety aspects of multiple antibiotic
resistant pathogens. He concluded that the projected
genetic frame of S. aureus isolates could be used for
developing further evaluation strategies and control
measures.
Dr. Satyendra Gautam, Head, Food Science and
Safety Section, Food Technology Division, Bhaha
Atomic Research Centre, Mumbai elucidated the idea of
targeting the pathways involved in drug resistance or by
inducing genetically regulated programmed cell death
(PCD) like process to control emerging antibiotic resis-
tance in pathogenic microbes.
Dr. Nivedita Sharma, Department of Basic Sciences,
Dr. Yashwant Singh Parmar University of Horticulture
and Forestry Nauni, Solan, described the food bio-pre-
servative potential of antimicrobial bacteriocins. She said
that food safety is an important issue of international
concern. Bio-preservation of food has emerged as an
attractive and safe approach for consumers. She said
that among biopreservatives, antimicrobial bacteriocin
biomolecules have caught the attention of food scientists
due to their unique properties of inhibiting food-borne
pathogens and spoilage-causing microorganisms without
expressing any resistance against them. In nature, many
microorganisms are capable of secreting novel bacterio-
cins exhibiting strong antagonism. However this poten-
tial of microorganisms has largely been untapped and so
far only nisin has got the commercial license for food
preservation. Thus, there is an urgent need to explore
the potential of different bacteriocin producing strains
belonging to lactic acid bacteria as well as Bacillus spp.
for the effective biopreservation of food. She further
highlighted some of the bacteriocins produced in their
research laboratory from different organisms. She
reported the effectiveness of lenticin, brevicin and subti-
lin against pathogenic bacteria viz., Listeria monocyto-
genes, Staphylococcus aureus, Aeromonas hydrophila,
Clostridium perfringens, Salmonella typhimurium,
Leuconostoc mesenteroides, Enterococcus faecalis, Pseu-
domonas aeruginosa and Escherichia coli. Further, the
efficacy of lenticin and nisin as biopreservative in cheese
inoculated with pathogenic bacteria was illustrated.
With the food safety point of view, she recommended
the use of bacteriocins as bio-preservatives.
Emergence, spread and environmental effect of
antimicrobial resistance
Dr. Rishi Shanker, Head, Environmental Microbiology
Division, Indian Institute of Toxicological Research,
Lucknow presented the keynote address on the topic
“Pathogenic bacteria and resistance to antimicrobial
agents: environmental sinks to aquatic landscapes”. He
started his address by quoting the Indian scenario, that
from the 23 macrocities, approximately 1500 million
litres of sewage/day is released and only 10% of them are
treated. As recorded by the Central Bureau of Health
Intelligence, Ministry of Health and Family Welfare,
there were 10.5 million cases of diarrhoea in 2003.
Approximately less than 30 million lives are lost annually
due to water related disease in India as per the estimates
of the World Bank.
Dr. Shanker stated that the microbiological quality of
water in the developing world in rural areas is poor due
to contamination by surface water run-offs, sewage
sludge, animal waste and lack of chlorine treatment.
However in the urban areas, the poor quality water is due
to inadequate filtration and chlorine treatment, prolifera-
tion of bacteria along the distribution system, inadequate
sewage systems, recreational use of surface water, ground
water contamination by septic effluent and no treatment
of urban storm water. The water sources contain total
coliforms comprising of faecal coliforms, Escherichia coli
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and pathogenic Escherichia coli (EHEC, ETEC, EPEC and
EAEC). He explained that E. coli being an indicator bac-
teria gets transmitted through ingestion of contaminated
water by human, meat, unpasteurized milk, water, fruits
and vegetables. For diarrheagenic E. coli, EHEC, EPEC
and ETEC the infectious dose is >10-200 cells.
He explained that for drug resistance and virulence
gene profiling of water quality, indicators E. coli and
Enterococci in surface waters are used. In a study con-
ducted in their laboratory, the occurrence of different
types of E. coli were isolated from water collected from
different sampling sites of the rivers Gomti, Saryu and
Ganga. They observed that pathogenic virulents of water
quality indicator were present in potable as well as sur-
face waters of the river Ganga and its tributaries Gomti
and Saryu. Using PCR based fingerprinting in E. coli iso-
lates from surface water of the rivers Gomti and Ganga,
they could locate the position of virulent genes. Antimi-
crobial resistance systems in enterotoxigenic E. coli
revealed multiple drug resistance in this most deadly
strain of E. coli prevalent in low hygienic areas, slum
areas and urban-rural interfaces. The markers like LT-1
and LT-2 in the genes were found to be most common
in these three rivers and hence were used for further
studies. Dr. Shanker said that the labile toxin (LT-1)
profile is present in approximately 68% of the subjects.
Without any seasonal variation LT-1 toxin producing
ETEC are present all through the year. LT-1 gene is a
target for culture independent quantitative detection by
real time PCR probes. Further in their studies it was
also reported that the aquatic flora from Gangetic river-
ines have been found to harbour high levels of ETEC.
They act as secondary reservoirs and release this organ-
ism from time to time in water bodies. Similar incidence
was also observed in vegetables grown on the river bank
and sediment samples of the river Ganga detected by
common probe system. Further profiling of Enterococci
as an indicator organism in their studies revealed that
MDR isolates could be recovered from different sites.
From the PCR based profiling of Enterococcus sp.
heterogeneity in the river Ganga with the order of
E. faecalis followed by E. faecium, E. durans, E. hirae
and other Enterococci was revealed.
Dr. Anita Arora, Microbiology consultant at the For-
tis Escorts Heart Institute, New Delhi illustrated the
high prevalence of Extended Spectrum Beta-lactamases
(ESBL’s) in Indian Medical Centres and multiple mode
of resistance mechanisms. She explained that ESBL’s are
associated with high mortality due to inappropriate
choice of antibiotics. This would eventually increase car-
bapenem use and may select resistance to these key
drugs. She concluded her talk with a call for efficient
infection control and implementation of other interven-
tion strategies.
Dr. V. S. Randhawa, Professor at the Department of
Microbiology, Lady Hardinge Medical College, New
Delhi explained that the prevalence of antibiotic resistant
strains is generally proportional to the extent of use of
any particular antibiotic in the area. In the study underta-
ken by him, the trends of ciprofloxacin resistance in
Klebsiella pneumoniae isolates from paediatric septicae-
mic cases were discussed. The possible reasons for
increased usage of ciprofloxacin figured out by him were
due to change of drug of choice for typhoid fever, treat-
ment of fever cases suspected for typhoid without investi-
gation, empiric use of ciprofloxacin without isolation of
the organism and performing susceptibility testing and
decrease in the cost of tablet. Dr. Randhawa recom-
mended the surveillance of antibiotic use at the national
level, sales of antibiotics from hospitals and drug stores
to be available from institutions, cities, states, countries
and continents, monitoring the prevalence of antibiotic
resistant bacteria, rational and judicious use of antibio-
tics, and use of synergistic combinations especially in
complicated situations. He further said that risk factors
for ciprofloxacin resistance as per long term use (> 20
days), dose (250 mg/bds) and hospital infection control,
should be considered to prevent spread of ciprofloxacin
resistant strains.
Prof. (Dr.) A. J. Tamhankar, Founder, Indian Initia-
tive for Management of Antibiotic Resistance, India
spoke on the elimination of antibiotic by sorption,
photolysis, hydrolysis and biodegradation. He explained
that antibiotics belonging to the group aminoglycosides
and b-lactamase are readily degradable while tetracy-
clines and quinolones undergo slow degradation when
sunlight exposure is limited. However, macrolides and
sulphonamides are least susceptible for degradation. He
reported that the hospital effluent waste water contains
antibiotics like ciprofloxacin, sulphamethoxazole, ery-
thromycin, norfloxacin, gentamycin and levofloxacin in
ng/ml to μg/ml concentrations. He concluded that one
has to be cautious about the phenomenon of antibiotic
resistance as it is an evolutionary phenomenon, besides;
human activity is adding and generating resistant bac-
teria to the environment.
Dr. Poornima Vajpayee, Scientist at the Environmental
Microbiology Division, Indian Institute of Toxicological
Research, Lucknow delivered a talk on the environmental
reservoirs of bacteria resistant to b-lactam antimicrobials.
She said that since antibiotics enter the environment from
farms, pharmaceutical factories, homes and hospitals, anti-
microbial resistant bacteria in the environment are a mat-
ter of concern. DNA carrying antimicrobial resistant genes
could be released to the environment after bacterial death
and can persist longer in the environment. Aquatic land-
scapes in populous countries are reservoirs to antimicro-
bial resistant pathogenic microbes due to indiscriminate
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use of antimicrobials in human and veterinary medicine
and addition of untreated sewage and other domestic
wastes from nearby planned and unauthorized settlements.
Dr. Vajpayee reported isolating blaTEM gene in surface
water collected from different sites in the river Gomti, in
street water, potable water and aquatic weeds suggesting
that blaTEM resistant genes may emerge as major contami-
nants in Gangetic plains in India. She said that aquatic
ecosystems as well as potable water serve as environmental
pools of b-lactam resistant genes that can potentially be
transferred to pathogens.
In her concluding remarks she stated that the infor-
mation on environmental reservoirs of genes conferring
resistance to antimicrobials of the b-lactam group preva-
lent in the Gangetic plains will be useful in formulating
strategies to protect the public from the menace of clini-
cal risks associated with antimicrobial resistant bacteria.
Computational modeling and the pro-drug
approach to combat antibiotic resistance
Prof. (Dr.) Indira Ghosh, Dean, School of Computational
and Integrative Sciences, Jawaharlal Nehru University,
New Delhi addressed on the in silico study using pathways
to inhibit the pathogenic bacteria, Mycobacterium tubercu-
losis. She said that drug development is difficult, costly and
time consuming; however, new antimicrobials are needed
to treat infections caused by ESKAPE (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, Enter-
obacter spp.) pathogens that currently cause the majority
of hospital infections. According to IDSA (Infectious Dis-
ease Society of America) the decreasing investment in
antibacterial drug development coupled with the increase
in antimicrobial resistance represents an “IMPENDING
DISASTER”, she quoted. Further, the challenges of anti-
tuberculosis drugs explained by her were: lengthy and
complicated nature for treatment of tuberculosis (i.e., 6-9
months), a course of four drug combinations (2 months =
isoniazid, rifampicin, pyrazinamide, ethambutol; 4-7
months = isoniazid and rifampicin) often leads to low
adherence (MDR & X-DR TB), treatment of TB-HIV co-
infection, drug–drug interaction between anti-TB and
antiretroviral (ritonivir) to counteract the effect of rifampi-
cin, treatment of persistent and latent TB infection, pre-
vention of active infection in high risk populations (people
in contact with TB infected or HIV positive people) and
treatment of pediatric patients. The goals of current anti-
TB development elucidated by her were to shorten and
simplify treatment for drug sensitive and MDR/XDR-TB,
TB co-infected with HIV that can be treated with anti-
retrovirals and latent TB infection. Besides these, improve-
ment of efficacy and safety of drugs, usability in multiple
populations and affordability were also stressed upon. She
stated that the drug discovery approaches in TB should
include genetic approaches to target identification (micro-
array expression analysis: to profile cellular responses to
perturbations or environmental stress, whole genome
sequencing), high throughput screening (whole cell [MIC]
or enzyme based [IC50] assay, HTS for known targets,
structural biology and virtual screening (docking: TB
structural genome), ligand-based approaches (QSAR
[quantitative structure-activity relationship], HQSAR
[hologram QSAR], 3D QSAR like CoMFA [comparative
molecular field analysis] and pharmacophore built using
machine learning techniques. She informed the activities
of TAACF [Tuberculosis antimicrobial acquisition and
coordinating facility] and TB alliance in this regard. She
further explained the strategies to kill an organism using
metabolic pathways comprising of two methods. Firstly, by
chemical flux through an essential metabolic pathway,
microbial load can be decreased to the point where life is
no longer possible. Secondly, an increase in the metabolic
concentration due to stop in enzyme activity to toxic levels
for the bacterium without harming the human.
The alternative targeting strategies from the recent
studies conducted in her laboratory as laid down by
Prof. Ghosh included using a comprehensive inhibitor of
ICL (isocitrate lyase) along with inhibition of ICD (isoci-
trate dehydrogenase) – kinase. She explained that inhibi-
tion of ICD-kinase would increase the amount of active
ICDs thus directly improving the efficacy of competitive
inhibition of ICLs by reducing the available isocitrate in
branch pathways. ICD-kinase as a potential target for
drugs against persistent Mycobacterium was also identi-
fied. Some of the in silico systems biological approaches
that assist in identification of various novel drug targets
in various pathogens outlined by her were: Flux Balance
Analysis (FBA), Metabolic Control Analysis (MCA),
Bayesian Analysis, Load Point and Choke Point Analysis,
Comparative Genomics and Microarray Analysis. She
finally concluded by stating that biology has traditionally
followed a reductionist approach in which individual
components of a living system are studied separately; we
need to reverse the process and study how these com-
ponents interact to form complex systems using an inte-
grative approach.
By quoting “Bad bugs need new drugs” Dr. Girish
Mahajan, Senior Group Head, Prokaryote Technology
and Antiinfective Discovery Division, Department of Nat-
ural Products, Piramal Life Sciences, Goregaon, Mumbai
continued the lecture, expressing the antibiotic market to
be very lucrative. He said there is an increasing demand
due to global spread of the MDR pathogen, emergence of
new virulent strains, the growing number of elderly and
immuno-compromised patients and the difficulty to treat
infections. He emphasized on microbial genomics as a
guide to drug discovery and structure elucidation as it is
a complementary tool to spectroscopy and enables rapid
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determination of complex structures. He further illu-
strated the genome analysis of compounds produced by
Streptomyces aizunensis NRRL B-11277 from literature.
This genome analysis has helped in identification of a
novel antifungal compound [ECO-02301]. The same
compound has been isolated in their laboratory from one
of the isolates. The MIC of ECO-2301 was not at par
with amphotericin-B. Further, there was evidence of cyto-
toxicity which hindered its further consideration for
development. He also said that genomic approaches may
take longer time as a way to identify the novelty in the
final bioactive compound.
The second approach discussed by him on antimicrobial
drug discovery was mutation. For this he showed an exam-
ple of Amycolata autrophica. The organism was initially
rejected because of lack of antimicrobial activity. However,
treatment of inactive wild strains then discarded in the
screening program was subject to intercalating agents ethi-
dium bromide or daunorubicin. This induced the culture
with very high frequency progeny which exhibited antibac-
terial activity. Antibacterial antibiotics 167-A and 167-B
were isolated from the fermentation broth of mutant EB5
derived from an inactive wild strain of Amycolata autro-
phica 167 by treatment with EB. The antibiotic 167 B was
identified as cervinomycin A2, component 167-A being a
new representative of the cervinomycin group. A large
number of mutants had to be screened with the mutation
process, which according to Dr. Mahajan was the limita-
tion of the method. The next approach found to be more
fruitful as addressed by Dr. Mahajan was isolation of novel
compounds from microbes in the marine environment.
Salinispora sp., a Gram positive aerobic non-acid fast bac-
teria isolated from marine sediments, was reported with
potential of compounds with anticancer, anti-inflamma-
tory, antibiotic and antiviral activities. He exemplified the
same by reporting the discovery of potent novel antibiotics
(PM181104 and PM181108) from marine resources by his
organization. Dr. Mahajan concluded his talk by saying
that India is a rich source of diverse microbes owing to its
large variations in climatic conditions and geographical
extremes. This asset has to be used especially by collabora-
tive research work with universities and industrial research
organizations towards getting novel compounds. The
active synthetic derivatives or microbial compounds
should be tested on panels of hundreds of test cultures to
strengthen their true trait; a strategy which may put us in
the frontiers of global drug research.
The term homeoinformatics was introduced by
Mr. Suchir Arora, Senior Consultant, Business and Deci-
sion, Gurgaon in order to model Homo sapiens biological
systems against antimicrobial resistance through homeop-
athy. He said that drug interactions of allopathic drugs are
well known, however for homeopathic drugs it has to be
developed since the molecules are not characterized.
He explained that conventional medications have options
for personalized medicines through the help of pharmaco-
genomics. But in the case of the homeopathic approach
the genetic, physical, emotional and personal health his-
tory etc. are followed. Hence more emphasis on individua-
lized medicine is given. For the homeopathic approach,
there is evidence from in vitro and in vivo streams facilitat-
ing our knowledge but much less work is done at in silico
level. So effort will be made to establish a new stream,
“homeoinformatics”, which will be a combination of bioin-
formatics and computer aided modelling. Application of
bioinformatics such as effective data mining, network biol-
ogy, systems biology etc. will be effective in understanding
the principles of homeopathy for more effective treatment.
He concluded by stating that in the primary steps compu-
tational modelling of homeopathic drugs is required to
combat disease with a special focus on antimicrobial resis-
tance. Later, we can exploit the possibility of establishing
new principles, algorithms, strategies in providing evidence
based support to the principles of homeopathy.
Regulatory issues of antimicrobial resistance
The Co-Chair of the CLSI Sub-Committee on Veterinary
Antibiotic Susceptibility Testing and Microbiology Tech-
nical Advisor at Elanco Animal Health, UK Dr. Shabir
Simjee delivered the first keynote lecture of this session
on harmonization in the generation, presentation and
application of antimicrobial susceptibility test data for bac-
teria of animal origin: the X08 report. He highlighted on
risk assessment, risk management and government legisla-
tion. He explained that the data generated from the sur-
veillance programs are used for registration purposes, as
an indicator for the emergence of resistance and, for
national risk assessment and subsequent risk management
guidelines. Dr. Simjee said that it is important to ensure
that the data being generated is of uniform quality and is
interpreted using single interpretive criteria. Pharmaceuti-
cal products should have risk assessment prior to registra-
tion or post-registration. He concluded that India does not
have a risk assessment process for drug companies to sub-
mit presently but that could change. It is not possible to
compare resistance rates from different surveillance
schemes (horizontal comparisons) as they are not measur-
ing the same parameter. Within national surveillance
schemes (vertical comparisons) methods of analysis have
changed overtime such that percentage resistance values
need to be viewed with caution. Further he demonstrated
that bacterial resistance showed varied antimicrobial sus-
ceptibility with respect to the source from where they are
isolated e.g., Escherichia coli of humans will show a differ-
ent antimicrobial susceptibility profile as compared to
birds and so on.
Resistance interpretation is done on the basis of the
clinical break point and epidemiological cut-off value
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(ECV). Because of discrepancies in interpretation of
data, the CLSI initiative on harmonization was underta-
ken. CLSI publishes three types of documents viz., stan-
dard, guidelines and report. For interpretation using the
standard method the details are to be strictly followed,
with the guidelines some modifications can be made in
methodology, while the report is a technical document
that is intended for informational use only and which
offers guidelines on how it should be done. He empha-
sized that the need for development of X08 – R is dri-
ven by the needs of the VAST (Veterinary Antimicrobial
Susceptibility Testing) group, confusion in use of com-
mon terms such as susceptible and resistance and use of
wild type or epidemiological cut-off values for reporting
results of national surveillance program. The benefits of
using ECV as outlined by him were: early detection of
resistance development in a given microbial population,
it is easier to develop than clinical breakpoint, can be
developed for any agent regardless of clinical usage and
can be incorporated into all clinical breakpoints. How-
ever it may not be predictive of clinical outcomes and
methods for setting ECVs are not yet standardized.
Dr. Simjee said that the clinicians look for clinical
breakpoint without caring for the wild and non-wild
type population. However, when the data on surveillance
is observed over a period of time clinical breakpoint is
of no value. Further to observe the trends, long term
surveillance programs are needed. So he recommended
from the X08 report the use of ECV rather than clinical
break point value. He further explained the need to
have universal adaptation of terminologies, and differen-
tiation of ECV and clinical break points. Further, data
obtained from Europe and the United States should not
to be taken at face value, as it can be challenged,
because the resistance and susceptibility standards of
these countries vary.
Dr. K. K. Tripathi, Advisor, and Member, Review
Committee on Genetic Manipulation, Department of
Biotechnology, Govt. of India, New Delhi presented the
second keynote address of this session. He spoke on the
regulation of genetically modified plants and use of anti-
biotic resistance markers. He said that the various
genetically modified organisms and r-DNA products are
governed by the Environmental Protection Act 1986,
Industries Development and Regulation Act 1951, Drugs
and Cosmetics Act 1940 and Pharmaceutical Policy
2002. He also talked about the various biosafety frame-
works in India which control the rules for manufacture,
use, import, export and storage of hazardous microor-
ganisms/genetically engineered organisms or cells (1989)
under the EPA 1986 [4]. These rules are very broad in
scope and cover the entire spectrum of activities relating
to research, development and use of Genetically Modi-
fied Organisms (GMOs) and their products. He said
that the regulatory system in India contains well defined
guidelines and documentation to generate quantitative
biological, ecological and agronomic supportive data.
There are multidisciplinary experts as reviewers at var-
ious stages of the development process. An extensive
safety assessment process is conducted in compliance
with international agreements and harmonization with
Codex/FAO/WHO. It also aims to ensure that GM
crops pose no risk to human and animal health, envir-
onmental safety and agriculture productivity. He said
that the antibiotic resistance markers are used in genetic
engineering as a tool for recognizing the successful
introduction of a new gene into a cell. Most antibiotic
resistance marker genes confer resistance by inactivating
the antibiotic through modifying enzymes. These anti-
biotic resistance genes are ubiquitous in the environ-
ment which is isolated from existing bacteria prevalent
in the environment. Some of the benefits of using anti-
biotic resistance markers for GE crops as counted by
him were: ideal selection system, simple selective proce-
dure, does not affect the physiology of cell, is cost effec-
tive and readily available. However, the biosafety
concerns of these include risk of horizontal gene trans-
fer from GM plants to micro-organisms particularly
genes conferring resistance to antibiotic. Though, hori-
zontal gene transfer (HGT) across different bacterial
taxa is well known, no examples of transfer of an anti-
biotic resistance determinant from transgenic plants to
bacteria have been found.
To date there is no well-defined mechanism for the
transfer of genes from plant cells to bacterial cells [5].
He concluded his lecture by stating that as per the
safety assessment of antibiotic resistance in GM crops
the decision of the International Food Biotechnology
Council, Food and Drug Administration (FDA), Envir-
onmental Protection Agency (EPA), World Health Orga-
nization (WHO) [6], The European Commission
Scientific Committees for Food and Animal Nutrition,
The Nordic Working Group on Food Toxicology and
Risk Assessment and European Food Safety Authority
(EFSA) states that the likelihood of transfer of antibiotic
resistance genes from GM plant to microorganisms, gas-
trointestinal tract microbes of man or animal, and in the
environment is remote.
Dr. G. J. Samathanam, Advisor and Head, Depart-
ment of Development and Transfer Division, Depart-
ment of Science and Technology, Govt. of India, New
Delhi spoke on the regulatory issues related to drug
development and emergence of multi-drug resistance in
modern antibiotics in the Indian context. He explained
the key aspects of right to health and compared it with
the data with respect to the economy, shifting pattern of
global pharmaceutical market, products, therapy forecast
and decadal progress of the pharmaceutical industry.
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He also presented an overview of the growth of the
Indian drug industry and predicted the possible growth
by 2015. Dr. Samathanam said that India’s annual health
expenditure is Rs.80,000 crores whereas both public and
private sector spending on research is Rs.1,150 crores
(1.4%). Medical research needs to be focused on thera-
peutic drugs/vaccines for tropical diseases which are
normally neglected by MNCs on account of their lim-
ited profitability potential. Emphasis needs to be on the
newly emerging frontier areas of research based on
genetics, genome based drugs and vaccine development,
molecular biology etc. He explained the agencies
involved in funding the research and the various steps
involved in the drug development process.
Dr. Samathanam then brought the attention of the
participants to the different antibiotics available for ther-
apeutic purposes and focussed on the emerging problem
of NDM-1. He said that the threat of this group of bac-
teria destabilises the disease management strategy and
makes it very complicated. He described that microbes
developing resistance to antibiotics is a well-established
truth. On the other hand, investment to develop new
antibiotics is increasing with decreasing return of effec-
tive, safe, affordable and successful antibiotics. For a
country like India to afford expensive, second line anti-
biotics is difficult. The unscrupulous use of first line
antibiotics is generating incidences of resistance among
the affected population especially for TB and other com-
municable diseases. He concluded his lecture by stating
that there is an urgent need to review the use of antibio-
tics in the country, generation of field data along with
infrastructure development to screen such antibiotic
resistant populations as well as segregation/isolation/
quarantine of such populations. He further emphasized
that to achieve this we require to have academic/phar-
maceutical/industry partnership in R&D through the
various funding agencies that encourage public-private
partnership R&D programmes in the Govt. of India.
Dr. Sadhna Srivastava, Scientist D, IPR Unit, Indian
Council of Medical Research, New Delhi said that the anti-
microbial resistance issue is not at the forefront in India.
She outlined her presentation on the following areas:
growing health concern especially in developing countries
and least developed countries, no new antimicrobials com-
ing in the market, very little interest by the pharma indus-
tries because it is not market driven, other options on how
to promote development of new antimicrobials, some reg-
ulatory issues with special focus on counterfeiting medi-
cines, national policy to combat the problem, possible
suggestions to streamline the regulatory procedure and
more importantly, the enforcement. She said that antimi-
crobial resistance is an alarming situation for communic-
able diseases. Further, no new antimicrobials are available
in the market due to disinterest of the pharma companies.
According to Professor Harrison, 1998 Nobel Laureate,
antimicrobial resistance is not a new phenomenon but it is
worrisome since this situation is accelerating and the tools
for identifying how to combat antimicrobial resistance are
not. This is not at the forefront for health policy makers.
Due to MDR there is increase in morbidity, mortality and
disability. The current scenario is still the same. The rea-
son is that in countries like India we are entangled with
problems with infectious diseases like tuberculosis,
malaria, leishmaniasis, etc. therefore resistance due to anti-
microbials is not the priority. In the last 5 years, 40%
increase in cephalosporin sale and 60% increase in usage
of antibiotics was reported by the Global Antibiotic Resis-
tance Partnership (GARP) [7]. There are two extreme con-
ditions. First, in India for the 4 lacs pneumococcal
infections in children they are not able to get antibiotics.
Secondly, there is irrational use of antibiotics in conditions
like cold, cough and dysentery where it is of no use.
Counterfeiting in antimicrobials has added new dimen-
sions towards resistance. The issue has magnified since
there is no clear definition of counterfeiting. Further, it
has generally covered sub-standard, spurious, misbranded
fake drugs and generics under the same bracket which
leads to regulatory and IP issues. She said that inexper-
ienced pharmacists are responsible for the irrational use of
antibiotics. Increasing drug pressure is the only reason for
evolution of resistance and removal of drug pressure does
not always lead to decrease in resistance. It is not only a
medical problem but a cumulative problem, including
social, cultural, economical, trade and global issues.
Further, transmissible resistance (on plasmids) is especially
problematic (classical example is NDM1 gene). Basically,
bacteria borne resistance is more dominant and hospital
and community acquired resistance is becoming more
common. This is due to spurious/poor quality antimicro-
bials. Drug resistance is growing in the South East Asian
Region with respect to malarial infection. About 95% of
the population are at moderate to high risk in India.
About 75% cases and over 50% deaths in the SEARO
region have been identified from India. There is an alarm-
ing increase in chloroquine resistant P. falciparum. Sulfa-
doxin pyrimethamine resistance is on the rise. MDR
P. falciparum has been reported. Deteriorating epidemio-
logical indices is associated with drug resistance. Thus the
whole scenario highlights the need for new antibiotics for
malaria. She further added that the current global R&D is
inadequate with respect to quantity and quality. The need
for antibiotics will thus continue to be high and will
increase because an ageing population needs new antimi-
crobials, increased global infection rates, increasing num-
bers of immuno-compromised patients and increasing
bacterial resistance. Therefore, more R&D is required. The
concerns of R&D for new antimicrobials are that most of
the research is done in the US and Western Europe. Basic
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research is generally on the wane as funding is coming
down, there are few new drugs, new drug pipelines are
near-dry and companies find it uneconomical to bring out
new antibiotics. Anti-microbials are not preferred by
pharma companies because drugs for life-style diseases
viz., heart disease, cholesterol-lowering agents, anti-inflam-
matories, diabetes mellitus or Alzheimer’s disease are
taken for prolonged periods. Long term returns on anti-
infectives has poor average revenue of antimicrobial
amounting to less than $500 million. (less than the $1.0
billion needed by a company). Many older agents are still
sold quite widely, as generics, giving reduced profits for
the innovator companies. Patent rights for several antiin-
fective drugs have either expired or will soon, for instance
co-amoxiclav (2001), ciprofloxacin (2004), clarithromycin,
azithromycin and ceftriaxone (2005) and levofloxacin
(2007).
She further explained the regulatory strategies in India
by highlighting the fact that there is little or no regulation
of antibiotics; particularly at pharmacies, susceptibility
testing and drug resistance are difficult in rural settings
and there is a need for national regulations which have
just been framed by the Directorate General of Health Ser-
vices, Ministry of Health and Family Welfare, Govt. of
India [8]. She highlighted on the new policies for contain-
ment of antimicrobial resistance in India and stated that
there are definite policies/guidelines for appropriate use of
antimicrobials at national level in specific national health
programs beings run in the country (e.g., RNTCP, national
AIDS control program etc.). For other diseases with public
health importance like enteric fever, diarrhoeal diseases,
respiratory infections etc., individual hospitals are follow-
ing their own policies and hospital infection control guide-
lines. To monitor antimicrobial resistance, it is necessary
to have: regulations for the use and misuse of antibiotics
in the country, creation of a national surveillance system
for antibiotic resistance, mechanisms for monitoring pre-
scription and regulatory provision for monitoring the use
of antibiotics in human, veterinary and industrial sectors
and identification of specific intervention measures for
rational use of antibiotics. She said that regulation is thus
a grey area because there are no publications. Only 20% of
WHO member states have some regulation on antimicro-
bials and these member states belong to the developed
countries, and 30% have no drug regulation primarily
represented by the developing and poor countries. Further
there is no clear cut information for the counterfeiting
whether it is intellectual property linked or public health
linked or a TRIPS-plus measure.
The definition of counterfeit given by the WHO is very
confusing and misleading because it is difficult to distin-
guish between spurious, substandard, misbranded and
counterfeit. Counterfeit drugs have been defined as those
which are deliberately or fraudently mislabelled with
respect to identity/source or both. It applies both to
brand and generic products; with correct or wrong ingre-
dients, with or without sufficient active ingredients and
with fake packaging including mislabelling. A substan-
dard drug is a genuine drug but does not meet the quality
specifications set for them. She emphasized that all the
pharmaceutical products have to comply with quality
standards and specifications before marketing. It should
have adequate shelf-life required by the territory of use
(e.g. high temperature in tropical countries) and should
be reviewed, assessed and approved by National Regula-
tory Authorities. Dr. Srivastava concluded her talk by
emphasizing that there is a need for streamlining regula-
tory procedures which can help in solving the problem of
antimicrobial resistance. National policy has been
initiated in India by Directorate General of Health Ser-
vices and Ministry of Health and Family Welfare in 2011.
Further, enforcement is a must for handling the menace
and global support is required for this. She assured that
the Indian Council of Medical Research, New Delhi has
taken the initiative to prepare guidelines on issues related
to antimicrobial and clinical trial registration and hope-
fully in 2-3 years some positive outcomes will be seen.
Dr. Mufti Suhail Sayeed, Vice President R&D and
Head, Clinical Operations at the Venus Medical Research
Centre, Panchkula, Haryana in his presentation explained
that strategies and tools are required for the management
of antimicrobial resistance rather than new drugs. This
can be attained with the help of a translational approach.
Dr. Sayeed said that there are 21 new antibacterial
compounds in the pipeline from developing companies.
Dalbovencin, which is in phase 3 of development, is con-
sidered to be one of the best drugs with a half-life of
10 days given once in a week. Dr. Sayeed explained that
organisms vary in their antibiotic resistance pattern with
respect to the environment and region. Antibiotic combi-
nations have been a success for many years to address
antibiotic resistance (AR) but still many antibiotic combi-
nations need to be studied. Hence an adjuvant approach
can be used to tackle the resistance problem. Antibiotic
adjuvants are defined as antibiotic combinations with
other strategies that enhance antimicrobial activity against
the pathogen. These are molecules that block antibiotic
resistance or antibiotic and non-antibiotic combinations.
As per the research conducted in Venus Medical Research
Centre, a novel molecule [VRP 1034 - Phytochemical] was
discovered as an antibiotic adjuvant. This compound was
reported to have the potential to inhibit efflux pump, stop
biofilm formation, act as a catalyst and provide synergy to
antibiotic combinations. It also makes the drug effective
against ESBL producing strains, prevents mutagenesis by
preventing conjugation, prevents resistance development
and decreases infection induced hepatotoxicity with its
antioxidant effect.
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Dr. Sayeed said that regulatory measures have to evolve
for guidelines to make adjuvants work. They are also
reported to work better than –penams. He said that with
the help of adjuvants, much of the effectiveness of antibio-
tics would be rejuvenated. He illustrated that novel combi-
nations with VRP 1034 (Renisil) were found to increase
the efficacy of antibiotics. As per the experiments con-
ducted at Venus Research Centre, Renisil caters to all
ESBL types viz., TEM, SHV, CTX-M and metallo-betalac-
tamase, effectively. Expression of outer membrane protein
was found to decrease with VRP 1034. The efficacy of
Renisil was found to be at par with meropenem in E. coli
and K. pneumoniae and superior with meropenem in
Pseudomonas aeruginosa. The expression of Mex AB pro-
tein (OMP) in P. aeruginosa was much diminished with
VRP 1034 adjuvant with antibiotic combination drug. It
also found to break bacterial biofilm, prevent conjuga-
tional transfer of F-plasmid, alter cell membrane porosity
and was considered safe as per the clinical studies con-
ducted. Dr. Sayeed further stated that national and inter-
national clinical trials are still in progress. It is also known
to reduce hospitalization time from 14 days to an average
of 7 days and the pharmacokinetics of individual drugs are
unaltered after adding VRP 1034. Improved safety and tol-
erability has been established by pre-clinical, Phase-III and
Phase-IV studies. It further has the potential to replace
Piperacillin, Tazobactum and save Meropenem as a
reserve drug which is also manufactured in EU GMP
approved facility.
Major achievements
The conference on antimicrobial resistance grabbed the
attention of academicians, clinicians, microbiologists,
scientists, biotechnologists, agriculturalists, environmental-
ist, R&D personnel and industrialists to share a common
platform to combat the menace. The event helped the
understanding of the issues related to emergence and
spread of antimicrobial resistance in a better way. National
level data pertaining to the recent surveillance studies of
various microorganisms was compared and analyzed. Spe-
cific intervention measures to harness the problem were
discussed. It helped in uniting the network of people
working on antimicrobial resistance to monitor the anti-
biotic susceptibility pattern among the clinical and envir-
onmental isolates. The event facilitated in identifying latest
technologies that could help in understanding the
mechanism of drug resistance and drug discovery.
Proposed future action plan
The National Conference on Antimicrobial Resistance
organized consecutively within a gap of three years gave
us a clear picture on the present status and progress
attained in this field at national level. As we are in pursuit
of tackling this menace with those who work on the issue,
we would like to further initiate network projects to gener-
ate surveillance data which will support in developing
appropriate guidelines. As we have identified the key per-
sonnel and centres involved in the research on antimicro-
bial resistance, we expect the national bodies and funding
agencies to support our projects on antimicrobial resis-
tance so that we may effectively contribute in the future
endeavours.
Conclusion
Prof. (Dr.) Rubina Lawrence, Organizing Secretary and
Convenor NCAR 2012 in her concluding remarks of the
conference stated that from the deliberations made dur-
ing these three days, four basic steps are needed in order
to achieve the interrelated goals of antimicrobial steward-
ship and development—strategies that were discussed
throughout the conference—and that have long been
advocated to address the threat of AR. These are: limit
the use of antimicrobials, discourage their misuse, reduce
infection through disease prevention measures and create
incentives for improved treatment and innovation. She
further hoped that the initiative of this conference
strengthens federal antimicrobial resistance surveillance,
prevention, control and research efforts as well as
enhances the collection of critical information on the use
and misuse of antimicrobial agents. The Hon’ble Vice
Chancellor Most Rev. (Prof.) Rajendra B. Lal during his
concluding remarks appreciated the efforts taken by the
organizing committee to unite national leaders and scien-
tists in this field to find a plausible solution.
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